Nature Communications (Apr 2022)

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine

  • Ofra Amir,
  • Yair Goldberg,
  • Micha Mandel,
  • Yinon M. Bar-On,
  • Omri Bodenheimer,
  • Nachman Ash,
  • Sharon Alroy-Preis,
  • Amit Huppert,
  • Ron Milo

DOI
https://doi.org/10.1038/s41467-022-29578-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 5

Abstract

Read online

This study compares SARS-CoV-2 infection rates following a recent second or third dose of the BNT162b2 (Pfizer/BioNTech) vaccine. They use data from Israel for 12–14 year olds (second dose) and 16–18 year olds (third dose), and find a 3.7-fold higher risk in the second-dose group.